RT Journal Article
SR Electronic
T1 When patients on target-specific oral anticoagulants need surgery
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 629
OP 639
DO 10.3949/ccjm.81a.13168
VO 81
IS 10
A1 Anderson, Mary
A1 Hassell, Kathryn L.
A1 Trujillo, Toby C.
A1 Wolfe, Brian
YR 2014
UL http://www.ccjm.org/content/81/10/629.abstract
AB The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and apixaban, are changing the way we manage thromboembolic disease. At the same time, many clinicians wonder how best to manage TSOAC therapy when patients need surgery. An in-depth understanding of these drugs is essential to minimize the risk of bleeding and thrombosis perioperatively.